Literature DB >> 1864285

Synergy and antagonism of combinations with quinolones.

H C Neu1.   

Abstract

Combinations of fluoroquinolones with other antimicrobial agents have been extensively investigated. Combinations of fluoroquinolones with aminoglycosides, beta-lactams, imidazoles, macrolides and clindamycin infrequently show synergy against Enterobacteriaceae and gram-positive bacteria. These combinations rarely show antagonism. Combinations of rifampin with fluoroquinolones tested against Staphylococcus aureus have been reported to show synergy and antagonism, and in vitro results have not correlated with results of animal infection experiments. Against Pseudomonas aeruginosa combinations of antipseudomonas penicillins or imipenem with fluoroquinolones are synergistic for 20% to 50% of isolates in vitro and also are synergistic in animal models of infection, whereas combinations of aminoglycosides with fluoroquinolones rarely show synergy against Pseudomonas aeruginosa. Against anaerobic species such as Bacteroides fragilis combinations of fluoroquinolones with clindamycin, anti-anaerobic penicillins, cephalosporins or imidazoles are occasionally synergistic but usually indifferent. Ciprofloxacin and ofloxacin combined with antituberculosis agents have activity against Mycobacterium tuberculosis and atypical mycobacteria. In general, fluoroquinolones should be combined with other agents not to achieve synergy, which is extremely variable, but to provide activity against bacteria inadequately inhibited by the fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864285     DOI: 10.1007/bf01966998

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  45 in total

1.  Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

Authors:  D M Bamberger; L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

2.  Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

Authors:  S M Smith; R H Eng; F Tecson-Tumang
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.

Authors:  W Kern; H Gulden; E Vanek; E Kurrle
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

4.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.

Authors:  N K Henry; M S Rouse; A L Whitesell; M E McConnell; W R Wilson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  In vitro susceptibility of Mycobacterium tuberculosis to ofloxacin and ciprofloxacin in combination with rifampin and isoniazid.

Authors:  M Casal; J Gutierrez; J González; P Ruiz
Journal:  Chemioterapia       Date:  1987-12

7.  Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.

Authors:  J A Moody; D N Gerding; L R Peterson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.

Authors:  L S Young; O G Berlin; C B Inderlied
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

9.  Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.

Authors:  C J Hackbarth; H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

10.  Evaluation of ciprofloxacin alone and in combination with other antibiotics in a murine model of thigh muscle infection.

Authors:  I Haller
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

View more
  18 in total

1.  Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.

Authors:  F Shojaee Aliabadi; M F Landoni; P Lees
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  D Bahl; D A Miller; I Leviton; P Gialanella; M J Wolin; W Liu; R Perkins; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

4.  Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

Authors:  D Beauchamp; G Laurent; L Grenier; P Gourde; J Zanen; J A Heuson-Stiennon; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

Authors:  E Gradelski; L Valera; D Bonner; J Fung-Tomc
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

7.  In vitro antimicrobial susceptibilities of Nocardia species.

Authors:  N Khardori; R Shawar; R Gupta; B Rosenbaum; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Preparation and evaluation of danofloxacin mesylate microspheres and its pharmacokinetics in pigs.

Authors:  Chunmei Wang; Diyun Ai; Cuilan Chen; Heng Lin; Jing Li; Hongchun Shen; Weixue Yi; Yuanhua Qi; Haigang Wu; Jiyue Cao
Journal:  Vet Res Commun       Date:  2009-09-23       Impact factor: 2.459

9.  Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa.

Authors:  San Tin; Kishore R Sakharkar; Chu Sing Lim; Meena K Sakharkar
Journal:  Int J Biol Sci       Date:  2009-01-21       Impact factor: 6.580

10.  In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.

Authors:  Devrim Dundar; Metin Otkun
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.